Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 3/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 5/20 | 0.34 |
| ▸ | CA2 | P00918 | 5/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Valrocemide SCHEMBL4014030 | 0.83 | HDAC7 (0.54) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7085943 | 0.81 | GRIK1 (0.34) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7085946 | 0.80 | HDAC7 (0.36) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7082795 | 0.78 | GRIK1 (0.46) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7085892 | 0.78 | GRIK1 (0.46) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7134376 | 0.77 | GRIK1 (0.37) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7081675 | 0.77 | GRIK1 (0.37) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7085940 | 0.75 | GRIK1 (0.36) | GRIK1GRIK2HDAC7HDAC8HDAC6 | |
| SCHEMBL7085945 | 0.74 | ERAP2 (0.40) | GRIK1GRIK2HDAC8HDAC1HDAC2 | |
| SCHEMBL139672 | 0.72 | CHRM1 (0.60) | GRIK1GRIK2HDAC7HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1330429-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-07-30 | — | — | EP | claimed |
| US-6521790-B2 | A most preferred compound is (2R)-2-propyl-4-hexynamide, an analog of valproic acid. treating seizures, migraine, psychiatric disorders, neuropathic pain and restlessness syndrome; neuroprotecting a cerebral insult; | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | claimed |
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | ABBVIE INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002036546-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-10 | — | — | WO | claimed |
| EP-1330429-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | Abbott Laboratories (US) | 2003-07-30 | — | — | EP | disclosed |
| US-6521790-B2 | A most preferred compound is (2R)-2-propyl-4-hexynamide, an analog of valproic acid. treating seizures, migraine, psychiatric disorders, neuropathic pain and restlessness syndrome; neuroprotecting a cerebral insult; | ABBOTT LABORATORIES | 2003-02-18 | — | — | US | disclosed |
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | ABBVIE INC. | 2002-09-05 | — | — | US | disclosed |
| WO-2002036546-A2 | ALKYNYL AMIDES AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123528-A1 | Alkynyl amides and their therapeutic applications | SCN1A, FAAH2, SCN1B | GRIK1 5/4885GRIK2 10/4885HDAC7 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.